



# **Phylogica**

## **2015 Annual General Meeting (PYC:ASX)**

**Peptide therapeutics against intracellular  
oncology targets**

# Disclaimer

The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) ['Phylogica']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Phylogica and should not be relied upon as an independent source of information. Please contact Phylogica and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.


Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Phylogica. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

# Phylogica's exciting transformation:

**From:**

A platform company using its proprietary Phylomer technology for drug discovery



**To:**

An cancer-focussed company developing first-in-class intracellular therapies using its disruptive drug discovery engine

# 2015 Highlights

- Completed \$10m capital raise in July, 2015
- Validated 'Best-in-Class' Phylomers for delivering *multiple* drug classes inside cells
- Major advances with in-house oncology pipeline:
- Progress with commercialisation:
  - Genentech collaboration
  - First non-exclusive license of Phylomer libraries to Phoremest



# Corporate Snapshot

| Shareholders     | %  |
|------------------|----|
| B. Hockings      | 28 |
| Sietsma Holdings | 9  |
| Swift            | 3  |
| Top 15           | 56 |

| Summary         |        |
|-----------------|--------|
| ASX             | PYC    |
| Cash (Sep/15)   | \$9.7m |
| Net Burn        | \$2.5m |
| Market Cap      | \$34m  |
| Shares on issue | 2,000m |

## *Executive Team*

Dr Richard Hopkins – CEO

Dr Paul Watt - CSO

## *Board of Directors*



**Bruce McHarrie**  
Chairman



**Dr Doug Wilson**  
NED



**Jeremy Curnock-Cook**  
NED



**Dr Bernard Hockings**  
NED




**Dr Richard Hopkins**  
CEO



# Core Technology


# Majority of drug targets (80%) are inside cells

## Intracellular Drug Targets




- PYC addressing unmet need to deliver biologic drugs inside cells!

# PYC: specialists for intracellular delivery of biologics




Potential to expand the druggable landscape by >10-fold!!

# The Problem: Drugs are unable to penetrate inside cells



# Superior cell penetrating Phylomers for delivering biologics drugs inside cells




- **Phylomer CPPs:** 'Best in Class' efficiency and safety for delivery of biologics



# **Phylomer CPPs: delivering new drug classes to expand the intracellular druggable landscape**

# MYC: A classic cancer target

- MYC: Is 'activated' in most human cancers (>50%) - recognised as a key driver of disease



- Considered undruggable by conventional drugs.
- Inhibiting MYC can eradicate existing tumours including lung, liver, pancreatic, blood and brain cancers
- ***OmoMYC:*** *most potent biologic Myc inhibitor*

# Phylomer CPP-Omomyc fusions are potent!


- Kills MYC-driven cancer cell lines with unprecedented potencies
- Improves efficacy of other cancer drugs up to **10X**.
- First to show CPP-Omomyc fusion can significantly reduce tumor size in an animal model of breast cancer.
- Identified Phylomers with better potency than OmoMYC gold standard ie. **'Best-in-Class' MYC Inhibitors**



# Phylogica's Proprietary Cancer Pipeline


# Phylogica's Intracellular Oncology Pipeline

- Phylomer screens against validated and clinically relevant oncology targets
- Validated hits already exceed potency of gold standard therapies



\*AML: Acute Myeloid Leukaemia

# Key phases to clinical development




# Focus on Leukaemia/Lymphoma

- Unmet clinical need - commercial opportunity
  - *Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia, Multiple Myeloma*
  - *Niche opportunities exist to control disease in patients awaiting transplant*
- Standard method of treatment is IV infusion,
- Provides direct access to blood-borne cancers
- Very good evidence for dependence on MYC and STAT5
- Engaging with key clinical experts



# **Preclinical phase opens key commercial opportunities**

# Major trend towards Preclinical and Phase 1 licensing



# Essential requirements for preclinical deals

| Feature   | PYC     |
|---|---------|
| Platform to address unique target landscape and unmet medical need.       | ✓       |
| Strong IP barriers and FTO  | ✓       |
| Well supported biological rationale for target                            | ✓       |
| Differentiated product/disruptive technology – ‘first-in-class’ therapies | ✓       |
| Potent PK/PD/Formulation in appropriate animal models                     | ongoing |
| Clear and compelling commercial target product profile (essential!)       | ongoing |

# Summary

- Advancing proprietary pipeline focused on blood cancers
- Developing 'first and best-in-class' therapies against challenging intracellular cancer targets
- Disruptive Phylomer engine for drug discovery and drug delivery
- Strategically positioned to realise commercial value for shareholders

# Thankyou!

# Contact Details

**Dr. Richard Hopkins**  
**Chief Executive Officer**  
Tel: +61 8 9489 7777  
Fax: +61 8 9489 7700  
Mobile: +61 405 656 868  
[richardh@phylogica.com](mailto:richardh@phylogica.com)

**Dr. Paul Watt**  
**Chief Scientific Officer**  
Tel: +61 8 9489 7777  
Fax: +61 8 9489 7700  
Mobile: +61 421 550 213  
[paulw@phylogica.com](mailto:paulw@phylogica.com)



[www.phylogica.com](http://www.phylogica.com)